|
Aptar Pharma dose indicator selected for new asthma combination therapy
Healthcare Packaging It is indicated for the maintenance treatment of asthma in patients aged 12 years and over (50/5?g and 125/5?g strengths), and in adults (250/10?g strength) whose symptoms are not adequately controlled on an ICS and an as-required inhaled short-acting … |
View full post on asthma – Google News